Welcome to the board Saltz! Completely agree. It is about time the shareholders like you that have been here for years, waiting, start to get rewarded. Lets get good financing behind us. Then maybe the discussion will turn fully to leronlimab instead of worrying about finding enough cash to finish the quarter. I am guessing this drug might end up being beneficial to 20%+ of all cancer patients. Hard to believe they can't scrap 30M dollars together, especially (assuming good data) they get tnbc numbers and other cancer mouse studies back this year, finish the BLA, get mono pivotal approved, start GvHD.